In Vitro Susceptibility of Clinical Isolates of Aspergillus spp. to Anidulafungin, Caspofungin, and Micafungin: a Head-to-Head Comparison Using the CLSI M38-A2 Broth Microdilution Method

被引:80
作者
Pfaller, M. A. [1 ]
Boyken, L. [1 ]
Hollis, R. J. [1 ]
Kroeger, J. [1 ]
Messer, S. A. [1 ]
Tendolkar, S. [1 ]
Diekema, D. J. [1 ,2 ]
机构
[1] Univ Iowa, Roy J & Lucille A Carver Coll Med, Dept Pathol, Iowa City, IA 52242 USA
[2] Univ Iowa, Roy J & Lucille A Carver Coll Med, Dept Med, Iowa City, IA 52242 USA
关键词
INVASIVE ASPERGILLOSIS; ECHINOCANDINS; RESISTANCE; FUMIGATUS; CANDIDA; DRUGS;
D O I
10.1128/JCM.01155-09
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
We determined the in vitro activities of anidulafungin, caspofungin, and micafungin against 526 isolates of Aspergillus spp. (64 A. flavus, 391 A. fumigatus, 46 A. niger, and 25 A. terreus isolates) collected from over 60 centers worldwide from 2001 through 2007. Susceptibility testing was performed according to the CLSI M38-A2 method. All three echinocandins-anidulafungin (50% minimum effective concentration [MEC(50)], 0.007 mu g/ml; MEC(90), 0.015 mu g/ml), caspofungin (MEC(50), 0.015 mu g/ml; MEC(90), 0.03 mu g/ml), and micafungin (MEC(50), 0.007 mu g/ml; MEC(90), 0.015 mu g/ml)-were very active against Aspergillus spp. More than 99% of all isolates were inhibited by <0.06 mu g/ml of all three agents.
引用
收藏
页码:3323 / 3325
页数:3
相关论文
共 17 条
[1]  
[Anonymous], 2008, APPROVED STANDARD M3
[2]   Comparative in vitro pharmacodynamics of caspofungin, micafungin, and anidulafungin against germinated and nongerminated Aspergillus conidia [J].
Antachopoulos, Charalampos ;
Meletiadis, Joseph ;
Sein, Tin ;
Roilides, Emmanuel ;
Walsh, Thomas J. .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2008, 52 (01) :321-328
[3]   Establishing in vitro-in vivo correlations for Aspergillus fumigatus:: the challenge of azoles versus echinocandins [J].
Arendrup, Maiken Cavling ;
Perkhofer, Susanne ;
Howard, Susan J. ;
Garcia-Effron, Guillermo ;
Vishukumar, Aimanianda ;
Perlin, David ;
Lass-Floerl, Cornelia .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2008, 52 (10) :3504-3511
[4]   The echinocandins [J].
Cappelletty, Diane ;
Eiselstein-McKitrick, Kasi .
PHARMACOTHERAPY, 2007, 27 (03) :369-388
[5]   Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis [J].
Denning, David W. ;
Marr, Kieren A. ;
Lau, Wendi M. ;
Facklam, David P. ;
Ratanatharathorn, Voravit ;
Becker, Cornelia ;
Ullmann, Andrew J. ;
Seibel, Nita L. ;
Flynn, Patricia M. ;
van Burik, Jo-Anne H. ;
Buell, Donald N. ;
Patterson, Thomas F. .
JOURNAL OF INFECTION, 2006, 53 (05) :337-349
[6]   Activities of caspofungin, itraconazole, posaconazole, ravuconazole, voriconazole, and amphotericin B against 448 recent clinical isolates of filamentous fungi [J].
Diekema, DJ ;
Messer, SA ;
Hollis, RJ ;
Jones, RN ;
Pfaller, MA .
JOURNAL OF CLINICAL MICROBIOLOGY, 2003, 41 (08) :3623-3626
[7]   Caspofungin susceptibility in Aspergillus and non-Aspergillus molds:: Inhibition of glucan synthase and reduction of β-D-1,3 glucan levels in culture [J].
Kahn, JN ;
Hsu, MJ ;
Racine, F ;
Giacobbe, R ;
Motyl, M .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2006, 50 (06) :2214-2216
[8]  
Larone DH, 2002, MED IMPORTANT FUNGI
[9]   Breakthrough invasive aspergillosis in allogeneic haematopoietic stem cell transplant recipients treated with caspofungin [J].
Madureira, Adrienne ;
Bergeron, Anne ;
Lacroix, Claire ;
Robin, Marie ;
Rocha, Vanderson ;
de Latour, Regis Peffault ;
Ferry, Christele ;
Devergie, Agnes ;
Lapalu, Jordane ;
Gluckman, Eliane ;
Socie, Gerard ;
Ghannoum, Mahmoud ;
Ribaud, Patricia .
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2007, 30 (06) :551-554
[10]   Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy [J].
Maertens, J ;
Raad, I ;
Petrikkos, G ;
Boogaerts, M ;
Selleslag, D ;
Petersen, FB ;
Sable, CA ;
Kartsonis, NA ;
Ngai, A ;
Taylor, A ;
Patterson, TF ;
Denning, DW ;
Walsh, TJ .
CLINICAL INFECTIOUS DISEASES, 2004, 39 (11) :1563-1571